

Ein cyf/Our ref: NICE TAs: letter 8

Gofynnwch am/Please ask for: Sue Beach

Rhif Ffôn /Telephone: 01554 783084

Ffacs/Facsimile:

E-bost/E-mail: sue.beach@wales.nhs.uk

Dr Iain Robertson-Steel
Withybush General Hospital
Fishguard Road, Haverfordwest,
Pembrokeshire, SA61 2PZ
Tel: 01437 764545

Dr Iain Robertson-Steel
Ysbyty Cyffredinol Llwynhelyg
Heol Abergwaun, Hwlfordd,
Sir Benfro, SA61 2PZ
Rhif Ffôn: 01437 764545

1st December 2014

BY EMAIL

Page 1 of 2

**TO: All prescribers
County lead pharmacists
Assistant Director of Nursing (Practice)
Hywel Dda Health Board global email**

Dear Colleague

The appraisals listed below have been published by the National Institute for Health & Care Excellence (NICE). They have been assessed for local implementation and their place in therapy established as described.

Please ensure that your teams are fully aware of this information.

In accordance with the provisions of Welsh Health Circulars WHC 2003 (109) and 2005 (22), see WHC (2003) 109 and WHC (2005) 22 (see links below), the drugs have been added to the Health Board's formulary (see links below), and are available for prescribing in accordance with the guidance.

Please ensure that the appropriate audit form is completed for all patient initiations on these technologies in the next 12 months. You will find the audit forms on the Clinical Systems (NICE / TA AWMSG appraisal audits) pages of the Health Board's Intranet (see link below).

Pharmacy has been notified of the guidance and you should be aware that a prescription that falls outside the recommendations of the guidance will be discussed with the prescriber. Failure to complete the audit form may result in a delay in dispensing.

If you have any questions relating to the guidance or this process, please contact Sue Beach, Lead Clinical Development Pharmacist, on 01554 783084 or 0777 21 77 655 or email sue.beach@wales.nhs.uk.

Dr Iain Robertson-Steel
Chairman, Medicines Management Group
AMD for Quality & Safety

(Signed copy kept on file)

Pencadlys Bwrdd Iechyd Prifysgol Hywel Dda
Llys Myrddin, Lôn Winch, Hwlfordd,
Sir Benfro, SA61 1SB
Rhif Ffôn: (01437) 771220
Rhif Ffacs: (01437) 771222

Hywel Dda University Health Board Headquarters
Merlins Court, Winch Lane, Haverfordwest,
Pembrokeshire, SA61 1SB
Tel No: (01437) 771220
Fax No: (01437) 771222

Cadeirydd / Chairman
Mrs Bernardine Rees OBE
Prif Weithredwr (Dros Dro) /
Chief Executive (Interim)
Mrs Karen Howell

Bwrdd Iechyd Prifysgol Hywel Dda yw enw gweithredol Bwrdd Iechyd Lleol Prifysgol Hywel Dda
Hywel Dda University Health Board is the operational name of Hywel Dda University Local Health Board

Mae Bwrdd Iechyd Prifysgol Hywel Dda yn amgylchedd di-fwg Hywel Dda University Health Board operates a smoke free environment

The Audit forms can be found on the Clinical Systems (NICE / TA AWMSG appraisal audits) pages of the Health Board's Intranet: <http://howis.wales.nhs.uk/sitesplus/862/page/43199>

- **NICE TA315 June 2014 Canagliflozin Type 2 diabetes**
<http://www.nice.org.uk/guidance/ta315/resources/guidance-canagliflozin-in-combination-therapy-for-treating-type2-diabetes-pdf>
APPROVED Primary & Secondary Care. **Second line to dapagliflozin**
Position in Diabetic Pathway:
Second line (Initiation by GP): in combination with metformin as an alternative to a gliptin. Consider before moving to a GLP-1 where weight loss is desirable. (BMI <30).
Third line (Initiation by Secondary Care and Insulin Initiating GPs): in combination with insulin.
Patient counselling required.
Monitoring Baseline: Check renal function: avoid if CrCl is less than 60mL/min at start of treatment. Six monthly: Hb_{1c} & weight. Only continue if adequate reductions maintained.
- **NICE TA320 August 2014 Dimethylfumarate (relapsing-remitting MS)**
<http://www.nice.org.uk/guidance/ta320/resources/guidance-dimethyl-fumarate-for-treating-relapsingremitting-multiple-sclerosis-pdf>
APPROVED Specialist Prescribing and Hospital Only (via ABMU Tertiary MS Service).
- **NICE TA321 October 2014 Dabrafenib (unresectable or metastatic BRAF V600 mutation -positive melanoma)** <http://www.nice.org.uk/guidance/ta321/resources/guidance-dabrafenib-for-treating-unresectable-or-metastatic-brafv600-mutationpositive-melanoma-pdf>
APPROVED Specialist Prescribing and Hospital Only
- **NICE TA316 July 2014 Enzalutamide (prostate cancer)**
<http://www.nice.org.uk/guidance/ta316/resources/guidance-enzalutamide-for-metastatic-hormonerelapsed-prostate-cancer-previously-treated-with-a-docetaxelcontaining-regimen-pdf>
APPROVED
 - For treating metastatic hormone-relapsed prostate cancer in adults whose disease has progressed during or after docetaxel-containing chemotherapy
 - Treatment of metastatic castration resistant prostate cancer in adult men whose disease has progressed and it is deemed that a docetaxel-containing chemotherapy regimen would have been the next course of therapy with a ECOG PS ≤2, but is contra-indicated (as per abiraterone non-NICE).
 - Sequential use of enzalutamide after abiraterone (or vice versa) following ABMU decision until the 27th January 2015 at which point this decision will be reviewed.

References:

Welsh Health Circulars WHC 2003 (109) (<http://howis.wales.nhs.uk/doclib/whc-2003-109-e.pdf>) and WHC (2005) 22 (http://howis.wales.nhs.uk/doclib/WHC_2005_022.pdf),
HDUHB Formulary: <http://hywelddahb.inform.wales.nhs.uk/>,

•